MESI-STRAT: Systems Medicine of Metabolic-Signaling Networks -A New Concept for Breast Cancer Patient Stratification.
Breast cancer is a complex disease with high prevalence in the European Union and world-wide. 75%-80 of the patients have estrogen receptor-positive (ER)-positive tumors and are treated with endocrine therapies. Endocrine therapies, which block ER-driven tumor growth, show high efficacy. Yet, a significant proportion of the patients will eventually relapse with metastatic breast
Programme: This Project is not associated with a Programme
Kynurenine formation by tryptophan-catabolic indoleamine-2,3-dioxygenase 1 (IDO1) plays a key role in tumor immune evasion and inhibition of IDO1 is efficacious in preclinical models of breast cancer.
Authors: Ines Heiland, Karl-Heinz Kellner, Sarah Schott, Christiane Opitz, Dewi D. L.,Mohapatra S. R.,Blanco Cabanes S.,Adam I.,Somarribas Patterson L. F.,Berdel B.,Kahloon M.,Thurmann L.,Loth S.,Heilmann K.,Weichenhan D.,Mucke O.,Wimberger P.,Kuhlmann J. D.,Plass C.,Platten M.,Gerhauser C.,Trump S.